Aqua: A New Questionnaire Assessing Anticholinergic Side Effects in Neurogenic Population (aqua: Anticholinergic Side Effects Questionnaire)

Aims. - Validate a new questionnaire to assess the side effects secondary to anticholinergics in neurogenic population suffering from Adult neurogenic lower urinary tract dysfunction (ANLUTD). Methods. - We conducted a prospective, monocentric study in a Neuro-urology Department of a University Hospital between February 2015 and April 2020. To allow a full psychometric validation of a questionnaire, the study protocol included 3 steps: qualitative interviews, feasibility study and validation study. The primary outcome was good psychometric properties defined with good internal consistency reliability (Cronbach's alpha > 0.7) and good test-retest reliability (intraclass correlation coefficient (ICC) > 0.7). Results. - we included 64 patients with ANLUTD secondary to neurogenic disorders. Feasibilitystudy demonstrate very good acceptation and comprehension for 97% of patients. Validationstudy showed good internal consistency with Cronbach's alpha = 0,69 and very good ICC = 0,73. AQUAis composed with 8 items scoring 0 (no side effect) to 2 (major side effect) for a total scorebetween 0 to 16. Time to fulfill is very quick. Mean score in our population was 4,1 (sd 2,9). Conclusion. - AQUA is the first validated tool to assess side effects secondary to antimuscarinictreatment for neurogenic population suffering from ANLUTD.